Literature DB >> 12901569

T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis.

Jingwu Zhang1.   

Abstract

Autoreactive T-cells are regulated under the normal conditions and play an important role in autoimmune pathologies when they are dysregulated as a result of genetic, environmental and other unknown factors associated with various autoimmune diseases. The immune regulation of autoreactive T-cells may be regained by activating the regulatory network, such as the idiotype anti-idiotypic network. Immunization with inactivated autoreactive T-cells (T-cell vaccination) can be used as a powerful means of activating the idiotype anti-idiotypic network to deplete specific subsets of autoreactive T-cells potentially involved in autoimmune conditions. It induces regulatory immune responses that closely resemble the in vivo situation, where the immune system is challenged by clonal activation and expansion of given T-cell populations in various autoimmune diseases. Recent clinical trials in multiple sclerosis have begun to reveal the role of T-cell vaccination in the understanding of in vivo regulation of autoreactive T-cells and in the development of effective therapeutic strategies for multiple sclerosis and other autoimmune conditions. In this article, we will review the recent advances in T-cell vaccination in relationship to the regulatory mechanism induced by T-cell vaccination and the potential of T-cell vaccination as a treatment for T-cell-mediated autoimmune diseases. Current issues and thoughts related to the preparation of T-cell vaccine, the relevant sources of autoimmune T-cells and epitope spreading are also discussed.

Entities:  

Mesh:

Year:  2002        PMID: 12901569     DOI: 10.1586/14760584.1.3.285

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  8 in total

Review 1.  Tregs in T cell vaccination: exploring the regulation of regulation.

Authors:  Irun R Cohen; Francisco J Quintana; Avishai Mimran
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

2.  Therapeutic effect of ergotope peptides on CIA by down-regulation of inflammatory and Th1/Th17 responses and induction of regulatory T cells.

Authors:  Xiaoyin Niu; Shaohua Deng; Shan Li; Yebin Xi; Chengzhen Li; Li Wang; Dongyi He; Zhaojun Wang; Guangjie Chen
Journal:  Mol Med       Date:  2016-08-30       Impact factor: 6.354

3.  CD4+ regulatory T cell responses induced by T cell vaccination in patients with multiple sclerosis.

Authors:  Jian Hong; Ying C Q Zang; Hong Nie; Jingwu Z Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-17       Impact factor: 11.205

Review 4.  Emerging immunopharmacological targets in multiple sclerosis.

Authors:  Mojtaba Farjam; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  J Neurol Sci       Date:  2015-09-14       Impact factor: 3.181

5.  Clone clusters in autoreactive CD4 T-cell lines from probable multiple sclerosis patients form disease-characteristic signatures.

Authors:  Mathilda Mandel; Anat Achiron; Tamir Tuller; Tilda Barliya; Gideon Rechavi; Ninette Amariglio; Ron Loewenthal; Gad Lavie
Journal:  Immunology       Date:  2009-10       Impact factor: 7.397

6.  Vaccination with single chain antigen receptors for islet-derived peptides presented on I-A(g7) delays diabetes in NOD mice by inducing anergy in self-reactiveT-cells.

Authors:  Werner Gurr; Margaret Shaw; Raimund I Herzog; Yanxia Li; Robert Sherwin
Journal:  PLoS One       Date:  2013-07-24       Impact factor: 3.240

7.  T cell vaccination inhibits Th1/Th17/Tfh frequencies and production of autoantibodies in collagen-induced arthritis.

Authors:  Shan Li; Xiaoyin Niu; Yebin Xi; Shaohua Deng; Chengzhen Li; Qing Zhao; Guangjie Chen
Journal:  Clin Dev Immunol       Date:  2013-12-02

Review 8.  Mechanisms of sex hormones in autoimmunity: focus on EAE.

Authors:  Ninaad Lasrado; Ting Jia; Chandirasegaran Massilamany; Rodrigo Franco; Zsolt Illes; Jay Reddy
Journal:  Biol Sex Differ       Date:  2020-09-07       Impact factor: 5.027

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.